Alpa Laboratories Q2 Results 2026: Net loss ₹2 Cr, Revenue ₹31 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹31Cr
- +18% YoY
- +29.5% QoQ
- Net profit
- −₹2Cr
- Q2 FY26: ₹0 Cr
- Margin
- −7.2%
- +1.3 pp YoY
- +9.3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Alpa Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Reported revenue from operations for the quarter ended 30th September 2026:. EBITDA for the quarter ended September 30, 2026: ₹684.1 million (Standalone) and ₹677.4 million (Consolidated); down 10.2% YoY Consolidated.
From Alpa Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Alpa Laboratories' revenue grow in the September 2026 quarter?
- Reported revenue from operations for the quarter ended 30th September 2026:
- Standalone: ₹3,097.56 lacs
- Consolidated: ₹3,097.56 lacs
- Year-on-year change in revenue from operations:
- Standalone: Increased from ₹2,563.21 lacs (Sep 25) to ₹3,097.56 lacs (Sep 26)
- Consolidated: Increased from ₹2,625.75 lacs (Sep 25) to ₹3,097.56 lacs (Sep 26)
- Other income (including unrealized profits from fair value gains):
2 more points from Alpa Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Alpa Laboratories' margins in Q2 FY27?
EBITDA for the quarter ended September 30, 2026: ₹684.1 million (Standalone) and ₹677.4 million…
Locked: what Alpa Laboratories Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Alpa Laboratories planning?
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Alpa Laboratories raising money or cutting debt?
However, it provides details on borrowings and related cash flows:
Locked: what Alpa Laboratories Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Alpa Laboratories' order book?
See what Alpa Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Alpa Laboratories Ltd — Quarterly revenue & net profit
Alpa Laboratories Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 31 | 26 | +18% | 24 | +29.5% |
| Operating profit (EBITDA) | -2 | -2 | — | -4 | — |
| Operating margin | -7.2% | -8.5% | +1.3 pp | -16.5% | +9.3 pp |
| Profit before tax | -2 | 0 | -1781.8% | 1 | -288.8% |
| Net profit (PAT) | -2 | 0 | -1781.8% | 1 | -288.8% |
| EPS (₹) | -0.85 | 0.05 | -1800% | 0.49 | -273.5% |
Source: Alpa Laboratories Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹31 Cr, net loss ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Aarey Drugs (Q2 FY27)
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alpa Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alpa Laboratories Ltd Q2 FY27 results?
Reported revenue from operations for the quarter ended 30th September 2026:. EBITDA for the quarter ended September 30, 2026: ₹684.1 million (Standalone) and ₹677.4 million (Consolidated); down 10.2% YoY Consolidated.
What is Alpa Laboratories Ltd share price analysis?
Alpa Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹124 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alpa Laboratories Ltd planning capital expenditure?
The presentation states the following on capex, capacity expansion, and new projects:.
Keep Alpa Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
